Delivering first-in-class immunotherapies
of activation and regulation
OSE Immunotherapeutics’ team has unique expertise and experience in immunological target discovery that serves as the basis for the development of innovative agonists and antagonists for application in immuno-oncology and autoimmune diseases.
We have already developed several first-in-class products that activate or regulate the immune system and cover a wide range of clinical indications, generating several academic and pharma partnerships.
OSE Immunotherapeutics’ pipeline is currently comprised of six developmental projects, four in immuno-oncology and two in autoimmune diseases. Five of our candidates are currently in the clinic.
- Indication NSCLC
- Pre-Clinical POC
- Phase 1
- Phase 2
- Phase 3 EU-US-lsr